Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Sells $41,934.69 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Victoria Vakiener sold 1,799 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the completion of the sale, the director now directly owns 30,205 shares of the company’s stock, valued at $704,078.55. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $25.22 on Thursday. The firm has a market capitalization of $3.12 billion, a P/E ratio of -9.07 and a beta of 0.78. The stock has a fifty day moving average price of $26.93 and a two-hundred day moving average price of $28.72. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $20.67 and a 52-week high of $41.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, February 6th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.46). The firm had revenue of $3.55 million for the quarter, compared to analyst estimates of $35.60 million. Arrowhead Pharmaceuticals had a negative return on equity of 90.77% and a negative net margin of 163.32%. The company’s revenue for the quarter was down 94.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.39) EPS. On average, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.7 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ARWR shares. HC Wainwright reissued a “buy” rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, February 8th. Royal Bank of Canada reissued an “outperform” rating and set a $50.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 7th. Morgan Stanley upped their target price on Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 7th. Finally, Citigroup lifted their price target on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.80.

Institutional Trading of Arrowhead Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ARWR. Van ECK Associates Corp boosted its holdings in shares of Arrowhead Pharmaceuticals by 22.9% in the 4th quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 447 shares in the last quarter. Fifth Third Bancorp raised its position in Arrowhead Pharmaceuticals by 112.0% in the 3rd quarter. Fifth Third Bancorp now owns 988 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Washington Trust Advisors Inc. acquired a new position in Arrowhead Pharmaceuticals in the fourth quarter worth $25,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Arrowhead Pharmaceuticals by 12.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,714 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 952 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in shares of Arrowhead Pharmaceuticals by 2.4% in the third quarter. New York State Common Retirement Fund now owns 42,866 shares of the biotechnology company’s stock valued at $1,152,000 after buying an additional 999 shares in the last quarter. 62.61% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.